Literature DB >> 17033537

The adipokine visfatin is markedly elevated in obese children.

Dominik G Haider1, Gregor Holzer, Georg Schaller, Daniel Weghuber, Kurt Widhalm, Oswald Wagner, Stylianos Kapiotis, Michael Wolzt.   

Abstract

OBJECTIVE: The insulin-mimetic adipocytokine visfatin has been linked to adiposity and the metabolic syndrome.
DESIGN: Cross-sectional study.
SUBJECTS: Eighty-three nondiabetic obese children and 40 healthy controls. MEASUREMENTS: We analyzed plasma visfatin concentrations to assess whether this adipokine is associated with adiposity.
RESULTS: Plasma visfatin concentrations were nearly 2-fold higher in obese children (mean, 1.1 ng/mL; 95% CI, 0.2-6.6) than in controls (0.6 ng/mL, 95% CI, 0.6 to 0.6; P < 0.001). No relationship was detectable between visfatin and other subject characteristics, hsCRP or the lipid profile.
CONCLUSIONS: Visfatin may be involved in the development of metabolic derangements in obese children.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17033537     DOI: 10.1097/01.mpg.0000235749.50820.b3

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  31 in total

Review 1.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

Review 2.  [Adipokines in healthy and obese children].

Authors:  G A Martos-Moreno; J J Kopchick; J Argente
Journal:  An Pediatr (Barc)       Date:  2012-11-24       Impact factor: 1.500

Review 3.  Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.

Authors:  Luis Rajman; Karolina Chwalek; David A Sinclair
Journal:  Cell Metab       Date:  2018-03-06       Impact factor: 27.287

4.  Study of Visfatin Level in Type 1 Diabetic Children and Adolescents.

Authors:  Mona H El Samahi; Nagwa Abdallah Ismail; Randa M Matter; Abeer Selim; Alshaymaa Ahmed Ibrahim; Walaa Nabih
Journal:  Open Access Maced J Med Sci       Date:  2017-06-11

5.  Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme.

Authors:  Javier R Revollo; Antje Körner; Kathryn F Mills; Akiko Satoh; Tao Wang; Antje Garten; Biplab Dasgupta; Yo Sasaki; Cynthia Wolberger; R Reid Townsend; Jeffrey Milbrandt; Wieland Kiess; Shin-Ichiro Imai
Journal:  Cell Metab       Date:  2007-11       Impact factor: 27.287

Review 6.  Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases.

Authors:  Shin-Ichiro Imai
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 7.  Regulation of cell survival and death by pyridine nucleotides.

Authors:  Shin-Ichi Oka; Chiao-Po Hsu; Junichi Sadoshima
Journal:  Circ Res       Date:  2012-08-17       Impact factor: 17.367

8.  Maternal visfatin concentration in normal pregnancy.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Edi Vaisbuch; Offer Erez; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Chia-Ling Nhan-Chang; Percy Pacora; Francesca Gotsch; Lami Yeo; Sun Kwon Kim; Samuel S Edwin; Sonia S Hassan; Pooja Mittal
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

9.  Visfatin in human pregnancy: maternal gestational diabetes vis-à-vis neonatal birthweight.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Edi Vaisbuch; Offer Erez; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Chia-Ling Nhan-Chang; Percy Pacora; Francesca Gotsch; Lami Yeo; Sun Kwon Kim; Samuel S Edwin; Sonia S Hassan; Pooja Mittal
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

10.  The novel adipocytokine visfatin exerts direct cardioprotective effects.

Authors:  Shiang Y Lim; Sean M Davidson; Ajeev J Paramanathan; Christopher C T Smith; Derek M Yellon; Derek J Hausenloy
Journal:  J Cell Mol Med       Date:  2008-04-08       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.